Entering text into the input field will update the search result below

BiolineRx reports FY16 results

  • BiolineRx (NASDAQ:BLRX) FY16 results: Revenues: $0; R&D Expense: $11.2M (-2.6%); SG&A: $5.3M (+12.8%); Operating Loss: ($16.5M) (-1.9%); Net Loss: ($15.8M) (-9.7%); Loss Per Share: ($0.28) (unch); Quick Assets: $35.6M (-25.4%).
  • No guidance given.
  • Shares are down 0.9% premarket.

Recommended For You

About BLRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BLRX--
BioLineRx Ltd.